OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy
Emanuele Rando, Francesco Vladimiro Segala, Joel Vargas, et al.
Antibiotics (2021) Vol. 11, Iss. 1, pp. 3-3
Open Access | Times Cited: 28
Emanuele Rando, Francesco Vladimiro Segala, Joel Vargas, et al.
Antibiotics (2021) Vol. 11, Iss. 1, pp. 3-3
Open Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
Navigating Available Treatment Options for Carbapenem-ResistantAcinetobacter baumannii-calcoaceticusComplex Infections
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Clinical Infectious Diseases (2023) Vol. 76, Iss. Supplement_2, pp. S179-S193
Open Access | Times Cited: 74
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Clinical Infectious Diseases (2023) Vol. 76, Iss. Supplement_2, pp. S179-S193
Open Access | Times Cited: 74
Acinetobacter baumannii in the critically ill: complex infections get complicated
Ilaria Cavallo, Alessandra Oliva, Rebecca Pages, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 55
Ilaria Cavallo, Alessandra Oliva, Rebecca Pages, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 55
Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis
Lorenzo Onorato, Ilaria de Luca, Caterina Monari, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106113-106113
Open Access | Times Cited: 18
Lorenzo Onorato, Ilaria de Luca, Caterina Monari, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106113-106113
Open Access | Times Cited: 18
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
Pierluigi Viale, Christian E. Sandrock, Paula Ramírez, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Pierluigi Viale, Christian E. Sandrock, Paula Ramírez, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study
Emanuele Rando, Salvatore Lucio Cutuli, Flavio Sangiorgi, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 24
Emanuele Rando, Salvatore Lucio Cutuli, Flavio Sangiorgi, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 24
Incidence of bloodstream infections due to multidrug-resistant pathogens in ordinary wards and intensive care units before and during the COVID-19 pandemic: a real-life, retrospective observational study
Francesco Vladimiro Segala, Pia Clara Pafundi, Maité Masciocchi, et al.
Infection (2023) Vol. 51, Iss. 4, pp. 1061-1069
Open Access | Times Cited: 23
Francesco Vladimiro Segala, Pia Clara Pafundi, Maité Masciocchi, et al.
Infection (2023) Vol. 51, Iss. 4, pp. 1061-1069
Open Access | Times Cited: 23
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence
Marin H. Kollef, Hervé Dupont, David E. Greenberg, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106882-106882
Open Access | Times Cited: 19
Marin H. Kollef, Hervé Dupont, David E. Greenberg, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106882-106882
Open Access | Times Cited: 19
Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study
Alessandra Oliva, L Liguori, S. Covino, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 6, pp. 1149-1160
Open Access | Times Cited: 7
Alessandra Oliva, L Liguori, S. Covino, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 6, pp. 1149-1160
Open Access | Times Cited: 7
Current and novel therapies for management of Acinetobacter baumannii -associated pneumonia
Aye Mya Sithu Shein, Parichart Hongsing, O’Rorke Kevin Smith, et al.
Critical Reviews in Microbiology (2024), pp. 1-22
Closed Access | Times Cited: 6
Aye Mya Sithu Shein, Parichart Hongsing, O’Rorke Kevin Smith, et al.
Critical Reviews in Microbiology (2024), pp. 1-22
Closed Access | Times Cited: 6
Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
Pasquale Sansone, Luca Gregorio Giaccari, Francesco Coppolino, et al.
Antibiotics (2022) Vol. 11, Iss. 7, pp. 904-904
Open Access | Times Cited: 23
Pasquale Sansone, Luca Gregorio Giaccari, Francesco Coppolino, et al.
Antibiotics (2022) Vol. 11, Iss. 7, pp. 904-904
Open Access | Times Cited: 23
Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series
Ángel Marcos‐Fendián, Marta Albanell‐Fernández, Montse Tuset, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1205-1216
Open Access | Times Cited: 14
Ángel Marcos‐Fendián, Marta Albanell‐Fernández, Montse Tuset, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1205-1216
Open Access | Times Cited: 14
Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic
Maddalena Giannella, Stefano Verardi, Andreas Karas, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 14
Maddalena Giannella, Stefano Verardi, Andreas Karas, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 14
Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence IS Aba36 in the siderophore receptor pirA
En Huang, Rebekah N. Thompson, Sun Hee Moon, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 7
Open Access | Times Cited: 5
En Huang, Rebekah N. Thompson, Sun Hee Moon, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 7
Open Access | Times Cited: 5
Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study
Cornelius J. Clancy, Oliver A Cornely, Stephen W. Marcella, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4427-4443
Open Access | Times Cited: 3
Cornelius J. Clancy, Oliver A Cornely, Stephen W. Marcella, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4427-4443
Open Access | Times Cited: 3
A review of recent advances in the treatment of adults with complicated urinary tract infection
Emanuele Rando, Francesca Giovannenze, Rita Murri, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 9, pp. 1053-1066
Closed Access | Times Cited: 12
Emanuele Rando, Francesca Giovannenze, Rita Murri, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 9, pp. 1053-1066
Closed Access | Times Cited: 12
Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019–2022
Andrew Chou, David J. Ramsey, Eva Amenta, et al.
Antimicrobial Stewardship & Healthcare Epidemiology (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 6
Andrew Chou, David J. Ramsey, Eva Amenta, et al.
Antimicrobial Stewardship & Healthcare Epidemiology (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 6
Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-Resistant Escherichia coli
Jia Hao Yeo, Nasren Begam, Wan Ting Leow, et al.
Microorganisms (2024) Vol. 12, Iss. 5, pp. 972-972
Open Access | Times Cited: 1
Jia Hao Yeo, Nasren Begam, Wan Ting Leow, et al.
Microorganisms (2024) Vol. 12, Iss. 5, pp. 972-972
Open Access | Times Cited: 1
Novel Antibiotics for Gram-Negative Nosocomial Pneumonia
Maria Panagiota Almyroudi, Aina Chang, Ioannis Andrianopoulos, et al.
Antibiotics (2024) Vol. 13, Iss. 7, pp. 629-629
Open Access | Times Cited: 1
Maria Panagiota Almyroudi, Aina Chang, Ioannis Andrianopoulos, et al.
Antibiotics (2024) Vol. 13, Iss. 7, pp. 629-629
Open Access | Times Cited: 1
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections
Alina Iovleva, Vance G. Fowler, Yohei Doi
Drugs (2024)
Closed Access | Times Cited: 1
Alina Iovleva, Vance G. Fowler, Yohei Doi
Drugs (2024)
Closed Access | Times Cited: 1
Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective
Daniele Roberto Giacobbe, Jason A. Roberts, Mohd H. Abdul‐Aziz, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 7, pp. 963-979
Closed Access | Times Cited: 6
Daniele Roberto Giacobbe, Jason A. Roberts, Mohd H. Abdul‐Aziz, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 7, pp. 963-979
Closed Access | Times Cited: 6
Multiplex PCR identification of the major Pseudomonas aeruginosa serogroups using specific novel target genes
Chu‐Fang Wang, Qinghua Ye, Jumei Zhang, et al.
LWT (2022) Vol. 163, pp. 113567-113567
Open Access | Times Cited: 6
Chu‐Fang Wang, Qinghua Ye, Jumei Zhang, et al.
LWT (2022) Vol. 163, pp. 113567-113567
Open Access | Times Cited: 6
Re: ‘Real world clinical outcome of cefiderocol for treatment of multidrug-resistant nonfermenting gram-negative bacilli infections' by Hoellinger et al.
Romaric Larcher, Paul Laffont-Lozes, Paul Loubet, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 6, pp. 808-811
Open Access | Times Cited: 3
Romaric Larcher, Paul Laffont-Lozes, Paul Loubet, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 6, pp. 808-811
Open Access | Times Cited: 3
Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia
Szymon Viscardi, Ewa Topola, Jakub Sobieraj, et al.
Antibiotics (2024) Vol. 13, Iss. 5, pp. 445-445
Open Access
Szymon Viscardi, Ewa Topola, Jakub Sobieraj, et al.
Antibiotics (2024) Vol. 13, Iss. 5, pp. 445-445
Open Access
Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China
Xiaoliang He, Jin Tang, S Q He, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Xiaoliang He, Jin Tang, S Q He, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Emergence and Evolution of OXA-23-Producing ST46Pas-ST462Oxf-KL28-OCL1 Carbapenem-Resistant Acinetobacter baumannii Mediated by a Novel ISAba1-Based Tn7534 Transposon
Haiyang Liu, Xiaochen Liu, Jintao He, et al.
Antibiotics (2023) Vol. 12, Iss. 2, pp. 396-396
Open Access | Times Cited: 1
Haiyang Liu, Xiaochen Liu, Jintao He, et al.
Antibiotics (2023) Vol. 12, Iss. 2, pp. 396-396
Open Access | Times Cited: 1
